Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM.

Epidemiology and infection

Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, DE Serres G.
PMID: 25115531
Epidemiol Infect. 2015 Apr;143(6):1332. doi: 10.1017/S0950268814002088. Epub 2014 Aug 13.

No abstract available.

Cite
Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM. Epidemiol Infect. 2014;143(6):1332doi: 10.1017/S0950268814002088.
Brisson, M., Edmunds, W. J., Law, B., Gay, N. J., Walld, R., Brownell, M., Roos, L. L., & DE Serres, G. (2015). Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM. Epidemiology and infection, 143(6), 1332. https://doi.org/10.1017/S0950268814002088
Brisson, M, et al. "Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM." Epidemiology and infection vol. 143,6 (2015): 1332. doi: https://doi.org/10.1017/S0950268814002088
Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, DE Serres G. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom - CORRIGENDUM. Epidemiol Infect. 2015 Apr;143(6):1332. doi: 10.1017/S0950268814002088. Epub 2014 Aug 13. PMID: 25115531.
Copy Download .nbib Format: NLM
Heterokaryon-Incompatibility Factor Interaction in Tests between Neurospora Mutants.

Science (New York, N.Y.)

De Serres FJ.
PMID: 17816561
Science. 1962 Dec 21;138(3547):1342-3. doi: 10.1126/science.138.3547.1342.

Studies on presumably isogenic ad-3A and ad-3B mutants of the ascomycete Neurospora crassa derived from the same wild-type strain have revealed that the negative heterokaryon tests shown by certain pairwise combinations can be attributed to interaction of incompatibility factor...

Cite
De Serres FJ. Heterokaryon-Incompatibility Factor Interaction in Tests between Neurospora Mutants. Science. 1962;138(3547):1342-3doi: 10.1126/science.138.3547.1342.
De Serres, F. J. (1962). Heterokaryon-Incompatibility Factor Interaction in Tests between Neurospora Mutants. Science (New York, N.Y.), 138(3547), 1342-3. https://doi.org/10.1126/science.138.3547.1342
De Serres, F J. "Heterokaryon-Incompatibility Factor Interaction in Tests between Neurospora Mutants." Science (New York, N.Y.) vol. 138,3547 (1962): 1342-3. doi: https://doi.org/10.1126/science.138.3547.1342
De Serres FJ. Heterokaryon-Incompatibility Factor Interaction in Tests between Neurospora Mutants. Science. 1962 Dec 21;138(3547):1342-3. doi: 10.1126/science.138.3547.1342. PMID: 17816561.
Copy Download .nbib Format: NLM
Hospitalizations for diarrhea in Quebec children from 1985 to 1998: estimates of rotavirus-associated diarrhea.

The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses

Buigues RP, Duval B, Rochette L, Boulianne N, Douville-Fradet M, Déry P, De Serres G.
PMID: 18159396
Can J Infect Dis. 2002 Jul;13(4):239-44. doi: 10.1155/2002/723804.

OBJECTIVE: To characterize the incidence and duration of hospitalization due to diarrhea and to assess the proportion of hospitalizations that are attributed to rotavirus-associated diarrhea.DESIGN: Retrospective study of hospitalization data.SETTING: Hospitals located in Quebec.POPULATION STUDIED: Children from one to...

Cite
Buigues RP, Duval B, Rochette L, et al. Hospitalizations for diarrhea in Quebec children from 1985 to 1998: estimates of rotavirus-associated diarrhea. Can J Infect Dis. 2002;13(4):239-44doi: 10.1155/2002/723804.
Buigues, R. P., Duval, B., Rochette, L., Boulianne, N., Douville-Fradet, M., Déry, P., & De Serres, G. (2002). Hospitalizations for diarrhea in Quebec children from 1985 to 1998: estimates of rotavirus-associated diarrhea. The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses, 13(4), 239-44. https://doi.org/10.1155/2002/723804
Buigues, René-Pierre, et al. "Hospitalizations for diarrhea in Quebec children from 1985 to 1998: estimates of rotavirus-associated diarrhea." The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 13,4 (2002): 239-44. doi: https://doi.org/10.1155/2002/723804
Buigues RP, Duval B, Rochette L, Boulianne N, Douville-Fradet M, Déry P, De Serres G. Hospitalizations for diarrhea in Quebec children from 1985 to 1998: estimates of rotavirus-associated diarrhea. Can J Infect Dis. 2002 Jul;13(4):239-44. doi: 10.1155/2002/723804. PMID: 18159396; PMCID: PMC2094881.
Copy Download .nbib Format: NLM
Canadian vaccine research networks: Vaccine safety resources for Canada.

Canada communicable disease report = Releve des maladies transmissibles au Canada

McCarthy J, Halperin SA, Bettinger JA, Langley JM, Crowcroft NS, Deeks S, Kwong JC, De Serres G, Top K, McNeil S, Scheifele DW.
PMID: 29769957
Can Commun Dis Rep. 2015 Feb 20;41:18-23. doi: 10.14745/ccdr.v41is1a04. eCollection 2015 Feb 20.

The Public Health Agency of Canada / Canadian Institutes of Health Research Influenza Research Network (PCIRN), established in 2009 to undertake evaluative research to inform public health decision making in Canada, is now being replaced by the Canadian Immunization...

Cite
McCarthy J, Halperin SA, Bettinger JA, et al. Canadian vaccine research networks: Vaccine safety resources for Canada. Can Commun Dis Rep. 2015;41:18-23doi: 10.14745/ccdr.v41is1a04.
McCarthy, J., Halperin, S. A., Bettinger, J. A., Langley, J. M., Crowcroft, N. S., Deeks, S., Kwong, J. C., De Serres, G., Top, K., McNeil, S., Scheifele, D. W. (2015). Canadian vaccine research networks: Vaccine safety resources for Canada. Canada communicable disease report = Releve des maladies transmissibles au Canada, 4118-23. https://doi.org/10.14745/ccdr.v41is1a04
McCarthy, J, et al. "Canadian vaccine research networks: Vaccine safety resources for Canada." Canada communicable disease report = Releve des maladies transmissibles au Canada vol. 41 (2015): 18-23. doi: https://doi.org/10.14745/ccdr.v41is1a04
McCarthy J, Halperin SA, Bettinger JA, Langley JM, Crowcroft NS, Deeks S, Kwong JC, De Serres G, Top K, McNeil S, Scheifele DW. Canadian vaccine research networks: Vaccine safety resources for Canada. Can Commun Dis Rep. 2015 Feb 20;41:18-23. doi: 10.14745/ccdr.v41is1a04. eCollection 2015 Feb 20. PMID: 29769957; PMCID: PMC5868603.
Copy Download .nbib Format: NLM
Core areas of practice and associated competencies for nurses working as professional cancer navigators.

Canadian oncology nursing journal = Revue canadienne de nursing oncologique

Cook S, Fillion L, Fitch M, Veillette AM, Matheson T, Aubin M, de Serres M, Doll R, Rainville F.
PMID: 23617218
Can Oncol Nurs J. 2013;23(1):44-62. doi: 10.5737/1181912x2314452.

UNLABELLED: Fillion et al. (2012) recently designed a conceptual framework for professional cancer navigators describing key functions of professional cancer navigation.PURPOSE: Building on this framework, this study defines the core areas of practice and associated competencies for professional cancer...

Cite
Cook S, Fillion L, Fitch M, et al. Core areas of practice and associated competencies for nurses working as professional cancer navigators. Can Oncol Nurs J. 2013;23(1):44-62doi: 10.5737/1181912x2314452.
Cook, S., Fillion, L., Fitch, M., Veillette, A. M., Matheson, T., Aubin, M., de Serres, M., Doll, R., & Rainville, F. (2013). Core areas of practice and associated competencies for nurses working as professional cancer navigators. Canadian oncology nursing journal = Revue canadienne de nursing oncologique, 23(1), 44-62. https://doi.org/10.5737/1181912x2314452
Cook, Sandra, et al. "Core areas of practice and associated competencies for nurses working as professional cancer navigators." Canadian oncology nursing journal = Revue canadienne de nursing oncologique vol. 23,1 (2013): 44-62. doi: https://doi.org/10.5737/1181912x2314452
Cook S, Fillion L, Fitch M, Veillette AM, Matheson T, Aubin M, de Serres M, Doll R, Rainville F. Core areas of practice and associated competencies for nurses working as professional cancer navigators. Can Oncol Nurs J. 2013;23(1):44-62. doi: 10.5737/1181912x2314452. French. PMID: 23617218.
Copy Download .nbib Format: NLM
Relative Severity of Common Human Coronaviruses and Influenza in Patients Hospitalized With Acute Respiratory Infection: Results From 8-Year Hospital-Based Surveillance in Quebec, Canada.

The Journal of infectious diseases

Gilca R, Carazo S, Amini R, Charest H, De Serres G.
PMID: 32761209
J Infect Dis. 2021 Mar 29;223(6):1078-1087. doi: 10.1093/infdis/jiaa477.

BACKGROUND: Few data exist concerning the role of common human coronaviruses (HCoVs) in patients hospitalized for acute respiratory infection (ARI) and the severity of these infections compared with influenza.METHODS: Prospective data on the viral etiology of ARI hospitalizations during...

Cite
Gilca R, Carazo S, Amini R, et al. Relative Severity of Common Human Coronaviruses and Influenza in Patients Hospitalized With Acute Respiratory Infection: Results From 8-Year Hospital-Based Surveillance in Quebec, Canada. J Infect Dis. 2021;223(6):1078-1087doi: 10.1093/infdis/jiaa477.
Gilca, R., Carazo, S., Amini, R., Charest, H., & De Serres, G. (2021). Relative Severity of Common Human Coronaviruses and Influenza in Patients Hospitalized With Acute Respiratory Infection: Results From 8-Year Hospital-Based Surveillance in Quebec, Canada. The Journal of infectious diseases, 223(6), 1078-1087. https://doi.org/10.1093/infdis/jiaa477
Gilca, Rodica, et al. "Relative Severity of Common Human Coronaviruses and Influenza in Patients Hospitalized With Acute Respiratory Infection: Results From 8-Year Hospital-Based Surveillance in Quebec, Canada." The Journal of infectious diseases vol. 223,6 (2021): 1078-1087. doi: https://doi.org/10.1093/infdis/jiaa477
Gilca R, Carazo S, Amini R, Charest H, De Serres G. Relative Severity of Common Human Coronaviruses and Influenza in Patients Hospitalized With Acute Respiratory Infection: Results From 8-Year Hospital-Based Surveillance in Quebec, Canada. J Infect Dis. 2021 Mar 29;223(6):1078-1087. doi: 10.1093/infdis/jiaa477. PMID: 32761209; PMCID: PMC7454730.
Copy Download .nbib Format: NLM
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.

Cell host & microbe

Tauzin A, Gong SY, Beaudoin-Bussières G, Vézina D, Gasser R, Nault L, Marchitto L, Benlarbi M, Chatterjee D, Nayrac M, Laumaea A, Prévost J, Boutin M, Sannier G, Nicolas A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Bo Y, Perreault J, Gokool L, Morrisseau C, Arlotto P, Bazin R, Dubé M, De Serres G, Brousseau N, Richard J, Rovito R, Côté M, Tremblay C, Marchetti GC, Duerr R, Martel-Laferrière V, Kaufmann DE, Finzi A.
PMID: 34953513
Cell Host Microbe. 2021 Dec 03; doi: 10.1016/j.chom.2021.12.004. Epub 2021 Dec 03.

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and...

Cite
Tauzin A, Gong SY, Beaudoin-Bussières G, et al. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host Microbe. 2021;doi: 10.1016/j.chom.2021.12.004.
Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., Laumaea, A., Prévost, J., Boutin, M., Sannier, G., Nicolas, A., Bourassa, C., Gendron-Lepage, G., Medjahed, H., Goyette, G., Bo, Y., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Bazin, R., Dubé, M., De Serres, G., Brousseau, N., Richard, J., Rovito, R., Côté, M., Tremblay, C., Marchetti, G. C., Duerr, R., Martel-Laferrière, V., Kaufmann, D. E., & Finzi, A. (2021). Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell host & microbe, . https://doi.org/10.1016/j.chom.2021.12.004
Tauzin, Alexandra, et al. "Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses." Cell host & microbe vol. (2021). doi: https://doi.org/10.1016/j.chom.2021.12.004
Tauzin A, Gong SY, Beaudoin-Bussières G, Vézina D, Gasser R, Nault L, Marchitto L, Benlarbi M, Chatterjee D, Nayrac M, Laumaea A, Prévost J, Boutin M, Sannier G, Nicolas A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Bo Y, Perreault J, Gokool L, Morrisseau C, Arlotto P, Bazin R, Dubé M, De Serres G, Brousseau N, Richard J, Rovito R, Côté M, Tremblay C, Marchetti GC, Duerr R, Martel-Laferrière V, Kaufmann DE, Finzi A. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host Microbe. 2021 Dec 03; doi: 10.1016/j.chom.2021.12.004. Epub 2021 Dec 03. PMID: 34953513; PMCID: PMC8639412.
Copy Download .nbib Format: NLM
Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study.

Infection control and hospital epidemiology

Longtin Y, Charest H, Quach C, Savard P, Baz M, Boivin G, Farfard J, Villeneuve J, Roger M, De Serres G.
PMID: 33427133
Infect Control Hosp Epidemiol. 2021 Jan 11;1-3. doi: 10.1017/ice.2020.1420. Epub 2021 Jan 11.

We performed viral culture of respiratory specimens in 118 severe acute respiratory coronavirus virus 2 (SARS-CoV-2)-infected healthcare workers (HCWs), ∼2 weeks after symptom onset. Only 1 HCW (0.8%) had a positive culture. No factors for prolonged viral shedding were...

Cite
Longtin Y, Charest H, Quach C, et al. Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infect Control Hosp Epidemiol. 2021;1-3doi: 10.1017/ice.2020.1420.
Longtin, Y., Charest, H., Quach, C., Savard, P., Baz, M., Boivin, G., Farfard, J., Villeneuve, J., Roger, M., & De Serres, G. (2021). Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infection control and hospital epidemiology, 1-3. https://doi.org/10.1017/ice.2020.1420
Longtin, Yves, et al. "Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study." Infection control and hospital epidemiology vol. (2021): 1-3. doi: https://doi.org/10.1017/ice.2020.1420
Longtin Y, Charest H, Quach C, Savard P, Baz M, Boivin G, Farfard J, Villeneuve J, Roger M, De Serres G. Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infect Control Hosp Epidemiol. 2021 Jan 11;1-3. doi: 10.1017/ice.2020.1420. Epub 2021 Jan 11. PMID: 33427133; PMCID: PMC7853751.
Copy Download .nbib Format: NLM
Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.

Cell host & microbe

Tauzin A, Gong SY, Beaudoin-Bussières G, Vézina D, Gasser R, Nault L, Marchitto L, Benlarbi M, Chatterjee D, Nayrac M, Laumaea A, Prévost J, Boutin M, Sannier G, Nicolas A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Bo Y, Perreault J, Gokool L, Morrisseau C, Arlotto P, Bazin R, Dubé M, De Serres G, Brousseau N, Richard J, Rovito R, Côté M, Tremblay C, Marchetti GC, Duerr R, Martel-Laferrière V, Kaufmann DE, Finzi A.
PMID: 34953513
Cell Host Microbe. 2021 Dec 03; doi: 10.1016/j.chom.2021.12.004. Epub 2021 Dec 03.

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and...

Cite
Tauzin A, Gong SY, Beaudoin-Bussières G, et al. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host Microbe. 2021;doi: 10.1016/j.chom.2021.12.004.
Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., Laumaea, A., Prévost, J., Boutin, M., Sannier, G., Nicolas, A., Bourassa, C., Gendron-Lepage, G., Medjahed, H., Goyette, G., Bo, Y., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Bazin, R., Dubé, M., De Serres, G., Brousseau, N., Richard, J., Rovito, R., Côté, M., Tremblay, C., Marchetti, G. C., Duerr, R., Martel-Laferrière, V., Kaufmann, D. E., & Finzi, A. (2021). Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell host & microbe, . https://doi.org/10.1016/j.chom.2021.12.004
Tauzin, Alexandra, et al. "Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses." Cell host & microbe vol. (2021). doi: https://doi.org/10.1016/j.chom.2021.12.004
Tauzin A, Gong SY, Beaudoin-Bussières G, Vézina D, Gasser R, Nault L, Marchitto L, Benlarbi M, Chatterjee D, Nayrac M, Laumaea A, Prévost J, Boutin M, Sannier G, Nicolas A, Bourassa C, Gendron-Lepage G, Medjahed H, Goyette G, Bo Y, Perreault J, Gokool L, Morrisseau C, Arlotto P, Bazin R, Dubé M, De Serres G, Brousseau N, Richard J, Rovito R, Côté M, Tremblay C, Marchetti GC, Duerr R, Martel-Laferrière V, Kaufmann DE, Finzi A. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host Microbe. 2021 Dec 03; doi: 10.1016/j.chom.2021.12.004. Epub 2021 Dec 03. PMID: 34953513; PMCID: PMC8639412.
Copy Download .nbib Format: NLM
SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Brousseau N, Morin L, Ouakki M, Savard P, Quach C, Longtin Y, Cheng MP, Carignan A, Dufresne SF, Leduc JM, Lavallée C, Gauthier N, Bestman-Smith J, Arrieta MJ, Ishak M, Lévesque S, Martin P, De Serres G.
PMID: 34903591
CMAJ. 2021 Dec 13;193(49):E1868-E1877. doi: 10.1503/cmaj.202783.

BACKGROUND: The COVID-19 pandemic has disproportionately affected health care workers. We sought to estimate SARS-CoV-2 seroprevalence among hospital health care workers in Quebec, Canada, after the first wave of the pandemic and to explore factors associated with SARS-CoV-2 seropositivity.METHODS:...

Cite
Brousseau N, Morin L, Ouakki M, et al. SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. CMAJ. 2021;193(49):E1868-E1877doi: 10.1503/cmaj.202783.
Brousseau, N., Morin, L., Ouakki, M., Savard, P., Quach, C., Longtin, Y., Cheng, M. P., Carignan, A., Dufresne, S. F., Leduc, J. M., Lavallée, C., Gauthier, N., Bestman-Smith, J., Arrieta, M. J., Ishak, M., Lévesque, S., Martin, P., & De Serres, G. (2021). SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 193(49), E1868-E1877. https://doi.org/10.1503/cmaj.202783
Brousseau, Nicholas, et al. "SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study." CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol. 193,49 (2021): E1868-E1877. doi: https://doi.org/10.1503/cmaj.202783
Brousseau N, Morin L, Ouakki M, Savard P, Quach C, Longtin Y, Cheng MP, Carignan A, Dufresne SF, Leduc JM, Lavallée C, Gauthier N, Bestman-Smith J, Arrieta MJ, Ishak M, Lévesque S, Martin P, De Serres G. SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. CMAJ. 2021 Dec 13;193(49):E1868-E1877. doi: 10.1503/cmaj.202783. PMID: 34903591; PMCID: PMC8677578.
Copy Download .nbib Format: NLM
Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada.

Preventive medicine reports

Gilca R, Billard MN, Zafack J, Papenburg J, Boucher FD, Charest H, Rochette M, De Serres G.
PMID: 32953425
Prev Med Rep. 2020 Aug 21;20:101180. doi: 10.1016/j.pmedr.2020.101180. eCollection 2020 Dec.

In Quebec, Canada, eligibility for palivizumab (PVZ) immunoprophylaxis was expanded in fall 2016 to include healthy-full-term (HFT) infants residing in the circumpolar region of Nunavik and aged

Cite
Gilca R, Billard MN, Zafack J, et al. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada. Prev Med Rep. 2020;20:101180doi: 10.1016/j.pmedr.2020.101180.
Gilca, R., Billard, M. N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada. Preventive medicine reports, 20101180. https://doi.org/10.1016/j.pmedr.2020.101180
Gilca, Rodica, et al. "Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada." Preventive medicine reports vol. 20 (2020): 101180. doi: https://doi.org/10.1016/j.pmedr.2020.101180
Gilca R, Billard MN, Zafack J, Papenburg J, Boucher FD, Charest H, Rochette M, De Serres G. Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada. Prev Med Rep. 2020 Aug 21;20:101180. doi: 10.1016/j.pmedr.2020.101180. eCollection 2020 Dec. PMID: 32953425; PMCID: PMC7484550.
Copy Download .nbib Format: NLM
SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Brousseau N, Morin L, Ouakki M, Savard P, Quach C, Longtin Y, Cheng MP, Carignan A, Dufresne SF, Leduc JM, Lavallée C, Gauthier N, Bestman-Smith J, Arrieta MJ, Ishak M, Lévesque S, Martin P, De Serres G.
PMID: 34903591
CMAJ. 2021 Dec 13;193(49):E1868-E1877. doi: 10.1503/cmaj.202783.

BACKGROUND: The COVID-19 pandemic has disproportionately affected health care workers. We sought to estimate SARS-CoV-2 seroprevalence among hospital health care workers in Quebec, Canada, after the first wave of the pandemic and to explore factors associated with SARS-CoV-2 seropositivity.METHODS:...

Cite
Brousseau N, Morin L, Ouakki M, et al. SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. CMAJ. 2021;193(49):E1868-E1877doi: 10.1503/cmaj.202783.
Brousseau, N., Morin, L., Ouakki, M., Savard, P., Quach, C., Longtin, Y., Cheng, M. P., Carignan, A., Dufresne, S. F., Leduc, J. M., Lavallée, C., Gauthier, N., Bestman-Smith, J., Arrieta, M. J., Ishak, M., Lévesque, S., Martin, P., & De Serres, G. (2021). SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 193(49), E1868-E1877. https://doi.org/10.1503/cmaj.202783
Brousseau, Nicholas, et al. "SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study." CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne vol. 193,49 (2021): E1868-E1877. doi: https://doi.org/10.1503/cmaj.202783
Brousseau N, Morin L, Ouakki M, Savard P, Quach C, Longtin Y, Cheng MP, Carignan A, Dufresne SF, Leduc JM, Lavallée C, Gauthier N, Bestman-Smith J, Arrieta MJ, Ishak M, Lévesque S, Martin P, De Serres G. SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study. CMAJ. 2021 Dec 13;193(49):E1868-E1877. doi: 10.1503/cmaj.202783. PMID: 34903591; PMCID: PMC8677578.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries